A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (NCT06741644)
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
Who can join: Review the eligibility criteria below.
Location: START Los Angeles, LLC — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- START Los Angeles, LLC — Los Angeles, California
- NEXT Dallas — Irving, Texas
- Alfred Hospital (Alfred Health) — Melbourne,
- Austin Hospital (Austin Health) — Melbourne,
- Monash Medical Centre (Monash Health) — Melbourne,
- Peter Maccallum Cancer Centre Research — Melbourne,
- Icon Cancer Centre South Brisbane — South Brisbane,
- Blacktown Hospital — Sydney,
- Macquarie University Hospital — Sydney,
- Scientia Clinical Research Ltd — Sydney,
- Beijing Cancer Hospital — Beijing,
- Jilin Cancer Hospital — Changchun,
- Hunan Cancer Hospital — Changsha,
- Sichuan Cancer Hospital — Chengdu,
- West China Hospital of Sichuan University — Chengdu,
- Fujian Cancer Hospital — Fuzhou,
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou,
- Sun Yat-Sen University Cancer Center — Guangzhou,
- The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou,
- Zhejiang Cancer Hospital — Hangzhou,
- Harbin Medical University Cancer Hospital — Harbin,
- Anhui Provincial Hospital — Hefei,
- Central Hospital Affiliated to Shandong First Medical University — Jinan,
- Linyi Cancer Hospital — Linyi,
- The First Affiliated Hospital of Nanchang University — Nanchang,
📞 Contact the Study Coordinator
Phone: +86 18017113282
Email: wangjingru@cstonepharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.